Release Date: 10/01/19 08:44 Summary: H1 FY2019 Preliminary Results - Continued Strong Growth Price Sensitive: Yes Download Document 682.28KB Download
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling